RU2020115287A - Новые молекулы искусственных нуклеиновых кислот - Google Patents
Новые молекулы искусственных нуклеиновых кислот Download PDFInfo
- Publication number
- RU2020115287A RU2020115287A RU2020115287A RU2020115287A RU2020115287A RU 2020115287 A RU2020115287 A RU 2020115287A RU 2020115287 A RU2020115287 A RU 2020115287A RU 2020115287 A RU2020115287 A RU 2020115287A RU 2020115287 A RU2020115287 A RU 2020115287A
- Authority
- RU
- Russia
- Prior art keywords
- utr
- fragment
- variant
- gene
- homologue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/076741 | 2017-10-19 | ||
| EPPCT/EP2017/076775 | 2017-10-19 | ||
| EP2017076775 | 2017-10-19 | ||
| EP2017076741 | 2017-10-19 | ||
| EPPCT/EP2018/057552 | 2018-03-23 | ||
| PCT/EP2018/057552 WO2018172556A1 (en) | 2017-03-24 | 2018-03-23 | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP2018076185 | 2018-09-26 | ||
| EPPCT/EP2018/076185 | 2018-09-26 | ||
| PCT/EP2018/078453 WO2019077001A1 (en) | 2017-10-19 | 2018-10-17 | NEW ARTIFICIAL NUCLEIC ACID MOLECULES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020115287A true RU2020115287A (ru) | 2021-11-19 |
| RU2020115287A3 RU2020115287A3 (https=) | 2022-02-28 |
Family
ID=66173912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020115287A RU2020115287A (ru) | 2017-10-19 | 2018-10-17 | Новые молекулы искусственных нуклеиновых кислот |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220233568A1 (https=) |
| EP (1) | EP3697912A1 (https=) |
| JP (3) | JP2021501572A (https=) |
| KR (2) | KR20250138817A (https=) |
| CN (1) | CN111630173A (https=) |
| AU (2) | AU2018351481B2 (https=) |
| BR (1) | BR112020004351A2 (https=) |
| CA (1) | CA3073634A1 (https=) |
| IL (2) | IL321714A (https=) |
| MX (2) | MX2020003995A (https=) |
| RU (1) | RU2020115287A (https=) |
| SG (1) | SG11202002186VA (https=) |
| WO (1) | WO2019077001A1 (https=) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| US12612654B2 (en) | 2016-02-12 | 2026-04-28 | CureVac SE | Method for analyzing RNA |
| US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3625363A1 (en) | 2017-05-17 | 2020-03-25 | CureVac Real Estate GmbH | Method for determining at least one quality parameter of an rna sample |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| CN111511924A (zh) | 2017-11-08 | 2020-08-07 | 库瑞瓦格股份公司 | Rna序列调整 |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| CN111511928A (zh) | 2017-12-21 | 2020-08-07 | 库瑞瓦格股份公司 | 偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法 |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| WO2019193183A2 (en) * | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| AU2019254591B2 (en) | 2018-04-17 | 2025-12-11 | CureVac SE | Novel RSV RNA molecules and compositions for vaccination |
| WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| CN114502204A (zh) | 2019-08-14 | 2022-05-13 | 库尔维科公司 | 具有降低的免疫刺激性质的rna组合和组合物 |
| US20220307017A1 (en) * | 2019-08-29 | 2022-09-29 | Universität Zürich | Minimal Messenger RNAs and uses thereof |
| CN110592223B (zh) * | 2019-10-31 | 2022-10-25 | 中南大学湘雅三医院 | 一种NSCLC的诊断和预后标记物hsa_circRNA_012515的应用 |
| CN112759652B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种嵌合抗原受体及其应用 |
| US12606822B2 (en) * | 2019-11-07 | 2026-04-21 | Icahn School Of Medicine At Mount Sinai | Synthetic modified RNA and uses thereof |
| CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US20230096704A1 (en) * | 2020-02-05 | 2023-03-30 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| EP4126030A1 (en) * | 2020-04-01 | 2023-02-08 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticle vaccine against sars-cov-2 |
| CN111413498B (zh) * | 2020-04-08 | 2023-08-04 | 复旦大学附属中山医院 | 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用 |
| CA3170740A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
| US20220017971A1 (en) * | 2020-07-15 | 2022-01-20 | Kookmin University Industry Academy Cooperation Foundation | Composition for predicting chemotherapy resistance of ovarian cancer and use thereof |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| US20230279408A1 (en) * | 2020-08-07 | 2023-09-07 | The Hong Kong University Of Science And Technology | Compositions and methods for increasing protein expression |
| US20230346921A1 (en) * | 2020-08-21 | 2023-11-02 | Peking University | Circular rna vaccines and methods of use thereof |
| EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| US20230383297A1 (en) * | 2020-10-09 | 2023-11-30 | Duke University | Novel targets for reactivation of prader-willi syndrome-associated genes |
| CN112280750B (zh) * | 2020-10-22 | 2022-11-01 | 山东农业大学 | 具有跨种传播能力的新型鹅星状病毒及其应用 |
| CN112526127B (zh) * | 2020-10-28 | 2022-12-06 | 四川大学华西医院 | 一种破伤风抗原的检测方法及其应用 |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| CN112574997B (zh) * | 2021-01-17 | 2023-07-21 | 楷拓生物科技(苏州)有限公司 | 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用 |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| JP2024508707A (ja) * | 2021-02-12 | 2024-02-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 熱ショックタンパク質９０結合ドメインを有する活性誘導型融合タンパク質 |
| CA3212653A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| CA3171429A1 (en) | 2021-03-31 | 2022-09-30 | Alexander SCHWENGER | Syringes containing pharmaceutical compositions comprising rna |
| CN113341152B (zh) * | 2021-04-27 | 2022-04-26 | 华南农业大学 | Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| US20240398933A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| CN115029349B (zh) * | 2022-06-09 | 2024-11-12 | 中国农业大学 | 与植物抗病性相关的circRNA、来源基因及其应用 |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| AU2023310896A1 (en) | 2022-07-19 | 2025-01-30 | Shenzhen Shenxin Biotechnology Co., Ltd. | Mrna for sars-cov-2 s protein and use thereof |
| AU2023353931A1 (en) | 2022-09-26 | 2025-03-20 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN115606550B (zh) * | 2022-10-28 | 2024-01-12 | 陆华 | 一种自身免疫性甲状腺炎诱导的卵巢储备功能低下动物模型的构建方法 |
| CN120112637A (zh) * | 2022-11-11 | 2025-06-06 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
| TW202430633A (zh) * | 2022-12-07 | 2024-08-01 | 科羅拉多大學董事會法人團體 | 新穎的ｈｉｖ－１變異體及其在動物激發模型中的使用方法 |
| CN120435560A (zh) | 2022-12-16 | 2025-08-05 | 深圳深信生物科技有限公司 | 提高rna分子翻译效率和/或稳定性的utr及其应用 |
| EP4660306A1 (en) | 2023-01-31 | 2025-12-10 | Synplogen Co., Ltd. | Artificially synthesized nucleic acid for increasing protein expression |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| CN116240175B (zh) * | 2023-02-28 | 2024-02-23 | 武汉科技大学 | 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用 |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024188312A1 (en) * | 2023-03-16 | 2024-09-19 | The Hong Kong University Of Science And Technology | Compositions and methods for enhanced protein expression |
| AU2024260120A1 (en) | 2023-04-27 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| EP4713483A1 (en) | 2023-05-16 | 2026-03-25 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2025027060A1 (en) * | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025040263A1 (en) | 2023-08-24 | 2025-02-27 | CureVac Manufacturing GmbH | Purification process for in vitro amplified dna |
| JP2025082576A (ja) * | 2023-11-17 | 2025-05-29 | アンジェス株式会社 | 核酸、医薬組成物、及び核酸を製造する方法 |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025246436A1 (en) * | 2024-05-29 | 2025-12-04 | Therorna Inc. | Circular rna-based therapeutic vaccine for treating hpv positive cancer |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN101307095A (zh) | 1996-06-14 | 2008-11-19 | 明治乳业株式会社 | T细胞表位肽 |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| EP1246597B1 (en) | 1999-08-03 | 2015-01-14 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| WO2010087791A1 (en) | 2009-01-27 | 2010-08-05 | Utc Power Corporation | Distributively cooled, integrated water-gas shift reactor and vaporizer |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US20110250264A1 (en) | 2010-04-09 | 2011-10-13 | Pacira Pharmaceuticals, Inc. | Method for formulating large diameter synthetic membrane vesicles |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| MX362981B (es) * | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
| WO2013143700A2 (en) * | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| CA2917348A1 (en) | 2013-07-11 | 2015-01-15 | Moderna Therapeutics, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
| MY174677A (en) | 2013-08-21 | 2020-05-06 | Curevac Ag | Composition and vaccine for treating lung cancer |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| CN111304231A (zh) * | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2935878C (en) | 2014-03-12 | 2023-05-02 | Curevac Ag | Combination of vaccination and ox40 agonists |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP3233113A1 (en) | 2014-12-16 | 2017-10-25 | CureVac AG | Ebolavirus and marburgvirus vaccines |
| EP3240558A1 (en) * | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| EP3317424B1 (en) * | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
| WO2017036580A1 (en) * | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
| SG10201913630YA (en) | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
| WO2018104540A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| SG11201906297QA (en) * | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
-
2018
- 2018-10-17 US US16/757,289 patent/US20220233568A1/en active Pending
- 2018-10-17 MX MX2020003995A patent/MX2020003995A/es unknown
- 2018-10-17 EP EP18789606.3A patent/EP3697912A1/en active Pending
- 2018-10-17 KR KR1020257029819A patent/KR20250138817A/ko active Pending
- 2018-10-17 IL IL321714A patent/IL321714A/en unknown
- 2018-10-17 BR BR112020004351-6A patent/BR112020004351A2/pt unknown
- 2018-10-17 JP JP2020521986A patent/JP2021501572A/ja active Pending
- 2018-10-17 CA CA3073634A patent/CA3073634A1/en active Pending
- 2018-10-17 RU RU2020115287A patent/RU2020115287A/ru unknown
- 2018-10-17 WO PCT/EP2018/078453 patent/WO2019077001A1/en not_active Ceased
- 2018-10-17 SG SG11202002186VA patent/SG11202002186VA/en unknown
- 2018-10-17 KR KR1020207012300A patent/KR102858623B1/ko active Active
- 2018-10-17 CN CN201880067696.6A patent/CN111630173A/zh active Pending
- 2018-10-17 AU AU2018351481A patent/AU2018351481B2/en active Active
-
2020
- 2020-02-23 IL IL272850A patent/IL272850A/en unknown
- 2020-07-13 MX MX2026002469A patent/MX2026002469A/es unknown
-
2023
- 2023-11-06 JP JP2023189376A patent/JP2024012523A/ja active Pending
-
2025
- 2025-02-10 AU AU2025200901A patent/AU2025200901A1/en active Pending
- 2025-05-30 JP JP2025090961A patent/JP2025131658A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025200901A1 (en) | 2025-02-27 |
| JP2021501572A (ja) | 2021-01-21 |
| IL272850A (en) | 2020-04-30 |
| RU2020115287A3 (https=) | 2022-02-28 |
| KR20200071081A (ko) | 2020-06-18 |
| BR112020004351A2 (pt) | 2020-09-08 |
| EP3697912A1 (en) | 2020-08-26 |
| AU2018351481A1 (en) | 2020-03-12 |
| MX2020003995A (es) | 2020-07-22 |
| US20220233568A1 (en) | 2022-07-28 |
| SG11202002186VA (en) | 2020-05-28 |
| WO2019077001A1 (en) | 2019-04-25 |
| IL321714A (en) | 2025-08-01 |
| AU2018351481B2 (en) | 2025-04-03 |
| CN111630173A (zh) | 2020-09-04 |
| JP2024012523A (ja) | 2024-01-30 |
| JP2025131658A (ja) | 2025-09-09 |
| KR102858623B1 (ko) | 2025-09-10 |
| KR20250138817A (ko) | 2025-09-22 |
| MX2026002469A (es) | 2026-04-01 |
| CA3073634A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020115287A (ru) | Новые молекулы искусственных нуклеиновых кислот | |
| JP2021501572A5 (https=) | ||
| JP7535489B2 (ja) | 治療用抗癌ネオエピトープワクチン | |
| CA2801218C (en) | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein | |
| RU2600798C2 (ru) | Композиции вакцин и способы их применения | |
| US20220111023A1 (en) | Neoepitope rna cancer vaccine | |
| RU2017138373A (ru) | Праймирование иммунного ответа | |
| JP7665205B2 (ja) | ネオエピトープをコードするコンストラクトを用いた核酸ワクチン接種 | |
| JP6377349B2 (ja) | Ｄｎａ発現構築物 | |
| WO2022071513A1 (ja) | ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン | |
| AU2022263537A1 (en) | Multivirus-specific t cell immunotherapy | |
| JP2026063215A5 (https=) | ||
| KR102906791B1 (ko) | mRNA의 세포내 안정성과 생합성을 향상시키는 UTR 서열을 포함하는 구성물과 그 사용 | |
| Wu et al. | Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors | |
| CN100588430C (zh) | 基于表位的SARS-Cov基因疫苗及其构建 | |
| CN105879060B (zh) | 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗 | |
| WO2025190157A1 (zh) | 一种治疗犬黑色素瘤的环状rna疫苗 | |
| CN101063142B (zh) | 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用 | |
| US12083189B2 (en) | Tail-conjugated RNAs | |
| CN116359509A (zh) | 一种用于胃癌治疗的肿瘤新抗原筛选方法和新型纳米疫苗的制备方法及应用 | |
| CN107722118A (zh) | 以FAPα的CTL表位肽为基础的肽类疫苗和微基因疫苗的应用 | |
| EP4364752A1 (en) | Improved vaccine | |
| CN121422199A (zh) | 一种协同敲低PCSK9基因表达的mRNA疫苗 | |
| You et al. | Distribution and expression of recombinant plasmid encoding chicken interleukin-2 | |
| CN118956861A (zh) | 一种基于重组MS2病毒样颗粒递送的HPV-16 E7circRNA疫苗 |